AstraZeneca-headquarters - Pharmaceutical Business review
Pharmaceutical Business review is using cookies
Continue
Learn More
Close
☰
Search
×
Home
About Us
Add Company
Advertise with us
Contact us
Events
Suplpiers
News
Clinical Trials
Drug Discovery
Packaging & Supply Chain
Production & Sales
Regulation
Advertise With Us
Advertise on our extensive network of industry websites and newsletters.
Get the PBR newsletter
Sign up to our free email to get all the latest PBR news.
Home
Drug Discovery
Drug Discovery
Research & Development
Pre-clinical Studies
Research & Development
Astellas and AI Proteins sign miniprotein therapeutics deal
Drug Discovery
Research & Development
Biotechnology
Sanofi and ScionxBio partner on mRNA therapies
Drug Discovery
Research & Development
Biotechnology
Clinical Trials
Clinical Trials
Patient Enrollment
Human Trials
Patient Enrollment
US FDA approves Avacta Group’s IND application for AVA6000
Clinical Trials
Patient Enrollment
AM-Pharma enrols first patients in Covid-19 phase III trial
Clinical Trials
Patient Enrollment
Regulation
Regulation
Drug Filing
Approvals
Rejections
Marketing Authorisation
Patents
Lawsuits
Drug Filing
Viatris files applications in Japan for approval of Effexor to treat GAD
Regulation
Drug Filing
Drug Manufacturing
Scholar Rock submits application of SMA therapy to FDA
Drug Filing
Drug Manufacturing
Production & Sales
Production & Sales
Manufacturing
Launches
Recalls
Marketing & Sales
Manufacturing
ENCell and Lucy Biotech forge alliance for mesenchymal stem cell therapy
Research & Development
Manufacturing
Merck introduces single-use reactor to accelerate ADC manufacturing
Manufacturing
Packaging & Supply Chain
Packaging & Supply Chain
Packaging
Cold Chain Distribution
Storage
Packaging
Uwe Röhrhoff Steps Down as Interim CEO of Gerresheimer AG
Packaging & Supply Chain
Packaging
Gerresheimer at CPHI Frankfurt 2025
Packaging
Suppliers
Suppliers
A-Z Suppliers
Products & Services
Videos
White Papers
No data found
Events
Register
Log In
AstraZeneca acquires Dogma’s oral PCSK9 inhibitor programme
AstraZeneca adds an oral PCSK9 inhibitor programme to its portfolio. Credit: AstraZeneca.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.